BIO-Europe® 2017: Axial CEO on microbiome use against autism
David Donabedian, CEO of Axial Biotherapeutics, chats with Mike Ward, head of content for Informa Pharma Insights, about using the microbiome to treat autism and why this R&D area is not just a passing phase. The pair discusses Axial’s technology, as well as the next steps for the emerging biotech which will enter the clinic in 2018. Axial is focused on the link between the human gut microbiome and the central nervous system; with its first clinical-stage asset the company is targeting patients with autism.